1
|
Yang W, Zhang J, Xiao Y, Li W, Wang T. Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones. Front Bioeng Biotechnol 2022; 10:858478. [PMID: 35782513 PMCID: PMC9247297 DOI: 10.3389/fbioe.2022.858478] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 05/23/2022] [Indexed: 12/20/2022] Open
Abstract
Chinese hamster ovary (CHO) cells are by far the most commonly used mammalian expression system for recombinant expression of therapeutic proteins in the pharmaceutical industry. The development of high-yield stable cell lines requires processes of transfection, selection, screening and adaptation, among which the screening process requires tremendous time and determines the level of forming highly productive monoclonal cell lines. Therefore, how to achieve productive cell lines is a major question prior to industrial manufacturing. Cell line development (CLD) is one of the most critical steps in the production of recombinant therapeutic proteins. Generation of high-yield cell clones is mainly based on the time-consuming, laborious process of selection and screening. With the increase in recombinant therapeutic proteins expressed by CHO cells, CLD has become a major bottleneck in obtaining cell lines for manufacturing. The basic principles for CLD include preliminary screening for high-yield cell pool, single-cell isolation and improvement of productivity, clonality and stability. With the development of modern analysis and testing technologies, various screening methods have been used for CLD to enhance the selection efficiency of high-yield clonal cells. This review provides a comprehensive overview on preliminary screening methods for high-yield cell pool based on drug selective pressure. Moreover, we focus on high throughput methods for isolating high-yield cell clones and increasing the productivity and stability, as well as new screening strategies used for the biopharmaceutical industry.
Collapse
Affiliation(s)
- Wenwen Yang
- Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, China
- International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang, China
| | - Junhe Zhang
- Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, China
- International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang, China
- Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang, China
- *Correspondence: Tianyun Wang, ; Junhe Zhang,
| | - Yunxi Xiao
- Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang, China
| | - Wenqing Li
- Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, China
| | - Tianyun Wang
- Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang, China
- International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang, China
- *Correspondence: Tianyun Wang, ; Junhe Zhang,
| |
Collapse
|
2
|
Zhou X, Wu H, Wen H, Zheng B. Advances in Single-Cell Printing. MICROMACHINES 2022; 13:80. [PMID: 35056245 PMCID: PMC8778191 DOI: 10.3390/mi13010080] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 12/27/2021] [Accepted: 12/30/2021] [Indexed: 12/20/2022]
Abstract
Single-cell analysis is becoming an indispensable tool in modern biological and medical research. Single-cell isolation is the key step for single-cell analysis. Single-cell printing shows several distinct advantages among the single-cell isolation techniques, such as precise deposition, high encapsulation efficiency, and easy recovery. Therefore, recent developments in single-cell printing have attracted extensive attention. We review herein the recently developed bioprinting strategies with single-cell resolution, with a special focus on inkjet-like single-cell printing. First, we discuss the common cell printing strategies and introduce several typical and advanced printing strategies. Then, we introduce several typical applications based on single-cell printing, from single-cell array screening and mass spectrometry-based single-cell analysis to three-dimensional tissue formation. In the last part, we discuss the pros and cons of the single-cell strategies and provide a brief outlook for single-cell printing.
Collapse
Affiliation(s)
| | | | | | - Bo Zheng
- Shenzhen Bay Laboratory, Institute of Cell Analysis, Shenzhen 518132, China; (X.Z.); (H.W.); (H.W.)
| |
Collapse
|
3
|
Tejwani V, Chaudhari M, Rai T, Sharfstein ST. High-throughput and automation advances for accelerating single-cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics production. Biotechnol Prog 2021; 37:e3208. [PMID: 34478248 DOI: 10.1002/btpr.3208] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 08/30/2021] [Accepted: 09/01/2021] [Indexed: 12/13/2022]
Abstract
Mammalian cell line development is a multistep process wherein timelines for developing clonal cells to be used as manufacturing cell lines for biologics production can commonly extend to 9 months when no automation or modern molecular technologies are involved in the workflow. Steps in the cell line development workflow involving single-cell cloning, monoclonality assurance, productivity and stability screening are labor, time and resource intensive when performed manually. Introduction of automation and miniaturization in these steps has reduced the required manual labor, shortened timelines from months to weeks, and decreased the resources needed to develop manufacturing cell lines. This review summarizes the advances, benefits, comparisons and shortcomings of different automation platforms available in the market for rapid isolation of desired clonal cell lines for biologics production.
Collapse
Affiliation(s)
- Vijay Tejwani
- Biotechnology R&D, Clone Development Team, Lupin Limited, Pune, India
| | - Minal Chaudhari
- Biotechnology R&D, Clone Development Team, Lupin Limited, Pune, India
| | - Toyaj Rai
- Biotechnology R&D, Clone Development Team, Lupin Limited, Pune, India
| | - Susan T Sharfstein
- College of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, New York, USA
| |
Collapse
|
4
|
Langsdorf E, Yu L, Kanevskaia L, Felkner R, Sturner S, McVey D, Khetan A. Retrospective assessment of clonal origin of cell lines. Biotechnol Prog 2021; 37:e3157. [PMID: 33896120 DOI: 10.1002/btpr.3157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 04/11/2021] [Accepted: 04/19/2021] [Indexed: 11/08/2022]
Abstract
Cell lines used for the manufacture of recombinant proteins are expected to arise from a single cell as a control strategy to limit variability and ensure consistent protein production. Health authorities require a minimum of two rounds of limiting dilution cloning or its equivalent to meet the requirement of single cell origin. However, many legacy cell lines may not have been generated with process meeting this criteria potentially impeding the path to commercialization. A general monoclonality assessment strategy was developed based on using the site of plasmid integration for a cell's identity. By comparing the identities of subclones from a master cell bank (MCB) to each other and that of the MCB, a probability of monoclonality was established. Two technologies were used for cell identity, Southern blot and a PCR assay based on plasmid-genome junction sequences identified by splinkerette PCR. Southern blot analysis revealed that subclones may have banding patterns that differ from each other and yet indicate monoclonal origin. Splinkerette PCR identifies cellular sequence flanking the point(s) of plasmid integration. The two assays together provide complimentary data for cell identity that enables proper monoclonality assessment and establishes that the three legacy cell lines investigated are all of clonal origin.
Collapse
Affiliation(s)
- Erik Langsdorf
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| | - Le Yu
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| | - Lioudmila Kanevskaia
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| | - Roland Felkner
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| | - Stephen Sturner
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| | - Duncan McVey
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| | - Anurag Khetan
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, New Brunswick, New Jersey, USA
| |
Collapse
|
5
|
Weinguny M, Klanert G, Eisenhut P, Jonsson A, Ivansson D, Lövgren A, Borth N. Directed evolution approach to enhance efficiency and speed of outgrowth during single cell subcloning of Chinese Hamster Ovary cells. Comput Struct Biotechnol J 2020; 18:1320-1329. [PMID: 32612755 PMCID: PMC7306589 DOI: 10.1016/j.csbj.2020.05.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 05/16/2020] [Accepted: 05/17/2020] [Indexed: 01/08/2023] Open
Abstract
Chinese Hamster Ovary (CHO) cells are the working horse of the pharmaceutical industry. To obtain high producing cell clones and to satisfy regulatory requirements single cell cloning is a necessary step in cell line development. However, it is also a tedious, labor intensive and expensive process. Here we show an easy way to enhance subclonability using subcloning by single cell sorting itself as the selection pressure, resulting in improved subcloning performance of three different host cell lines. These improvements in subclonability also lead to an enhanced cellular growth behavior during standard batch culture. RNA-seq was performed to shed light on the underlying mechanisms, showing that there is little overlap in differentially expressed genes or associated pathways between the cell lines, each finding their individual strategy for optimization. However, in all three cell lines pathways associated with the extracellular matrix were found to be enriched, indicating that cells struggle predominantly with their microenvironment and possibly lack of cell-to-cell contact. The observed small overlap may hint that there are multiple ways for a cell line to achieve a certain phenotype due to numerous genetic and subsequently metabolic redundancies.
Collapse
Key Words
- CHO
- CHO cells
- CHO, Chinese hamster ovary
- Cell line development
- Cell sorting
- Chinese Hamster Ovary Cells
- CoI, clusters of interest
- DE, directed evolved
- Directed Evolution
- ECM, extracellular matrix
- ES, enrichment score
- FACS
- FACS, fluorescent-activated cell sorting
- Fluorescent-activated cell sorting
- GSEA, gene set analysis
- Growth enhancement
- Growth improvement
- LDC, limiting dilution cloning
- NES, negative enrichment score
- PC, principal component
- PCA, principal component analysis
- POI, product of interest
- RNA Sequencing
- RNA-Seq
- RNA-Seq, RNA sequencing
- SCC, single cell cloning
- Single Cell Cloning
- Single Cell Subcloning
- Subcloning
- lfcSE, logfoldstandard error
Collapse
Affiliation(s)
- Marcus Weinguny
- ACIB Gmbh, Austrian Centre of Industrial Biotechnology, Vienna, Austria
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Vienna, Austria
| | - Gerald Klanert
- ACIB Gmbh, Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Peter Eisenhut
- ACIB Gmbh, Austrian Centre of Industrial Biotechnology, Vienna, Austria
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Vienna, Austria
| | | | | | | | - Nicole Borth
- ACIB Gmbh, Austrian Centre of Industrial Biotechnology, Vienna, Austria
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Vienna, Austria
- Corresponding author at: Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria.
| |
Collapse
|
6
|
Chen C, Xu D, Bai S, Yu Z, Zhu Y, Xing X, Chen H. Dynamic screening and printing of single cells using a microfluidic chip with dual microvalves. LAB ON A CHIP 2020; 20:1227-1237. [PMID: 32100799 DOI: 10.1039/d0lc00040j] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Inoculation of single cells into separate culture chambers is one of the key requirements in single-cell analysis. This paper reports an innovative microfluidic chip integrating two pneumatic microvalves to screen and print single cells onto a well plate. The upper and lower size limits of cells can be dynamically controlled by regulating the deformation of two adjacent microvalves. Numerical simulations were employed to systematically study the influence of membrane dimensions and pressure on the deflection of a valve. A mathematical model was then modified to predict the size of cells captured by a microvalve at various pressures. The membrane deflection was further studied using confocal imaging. The critical pressure trapping beads of various sizes was experimentally determined. These experiments validated the accuracy of both numerical simulations and the mathematical model. Furthermore, single beads and endothelial cells with the desired size range were screened using dual valves and printed onto well plates with 100% efficiency. Viability studies suggested that the screening process had no significant impact on cells. This device enables dynamic regulation of both the lower and the upper size limits of cells for printing. It has significant application potential in inoculating cells with desired sizes for various fields such as clonal expansion, monoclonality development and single-cell genomic studies.
Collapse
Affiliation(s)
- Chang Chen
- School of Mechanical Engineering and Automation, Harbin Institute of Technology, Shenzhen, Shenzhen 518055, China.
| | | | | | | | | | | | | |
Collapse
|
7
|
Chen C, Le K, Le H, Daris K, Soice N, Stevens J, Goudar CT. Methods for Estimating the Probability of Clonality in Cell Line Development. Biotechnol J 2020; 15:e1900289. [DOI: 10.1002/biot.201900289] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2019] [Revised: 10/20/2019] [Indexed: 12/18/2022]
Affiliation(s)
- Chun Chen
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Kim Le
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Huong Le
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Kristi Daris
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Neil Soice
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Jennitte Stevens
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Chetan T. Goudar
- Drug Substance TechnologiesProcess Development Amgen Inc., 1 Amgen Center Drive Thousand Oaks CA 91320 USA
| |
Collapse
|
8
|
Louie S, Heidersbach A, Blanco N, Haley B, Rose CM, Liu PS, Yim M, Tang D, Lam C, Sandoval WN, Shaw D, Snedecor B, Misaghi S. Endothelial intercellular cell adhesion molecule 1 contributes to cell aggregate formation in CHO cells cultured in serum‐free media. Biotechnol Prog 2020; 36:e2951. [DOI: 10.1002/btpr.2951] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 11/14/2019] [Accepted: 12/11/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Salina Louie
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Amy Heidersbach
- Molecular Biology DepartmentGenentech, Inc. South San Francisco California
| | - Noelia Blanco
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Benjamin Haley
- Molecular Biology DepartmentGenentech, Inc. South San Francisco California
| | - Christopher M. Rose
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - Peter S. Liu
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - Mandy Yim
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Danming Tang
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Cynthia Lam
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Wendy N. Sandoval
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - David Shaw
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Brad Snedecor
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Shahram Misaghi
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| |
Collapse
|
9
|
Le K, Tan C, Le H, Tat J, Zasadzinska E, Diep J, Zastrow R, Chen C, Stevens J. Assuring Clonality on the Beacon Digital Cell Line Development Platform. Biotechnol J 2019; 15:e1900247. [DOI: 10.1002/biot.201900247] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2019] [Revised: 09/27/2019] [Indexed: 12/20/2022]
Affiliation(s)
- Kim Le
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Christopher Tan
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Huong Le
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Jasmine Tat
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Ewelina Zasadzinska
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Jonathan Diep
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Ryan Zastrow
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Chun Chen
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| | - Jennitte Stevens
- Drug Substance TechnologiesProcess DevelopmentAmgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 USA
| |
Collapse
|
10
|
Welch JT, Arden NS. Considering “clonality”: A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development. Biologicals 2019; 62:16-21. [DOI: 10.1016/j.biologicals.2019.09.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/13/2019] [Accepted: 09/16/2019] [Indexed: 12/23/2022] Open
|
11
|
Wang B, Albanetti T, Miro-Quesada G, Flack L, Li L, Klover J, Burson K, Evans K, Ivory W, Bowen M, Schoner R, Hawley-Nelson P. High-throughput screening of antibody-expressing CHO clones using an automated shaken deep-well system. Biotechnol Prog 2018; 34:1460-1471. [PMID: 30298994 PMCID: PMC6587815 DOI: 10.1002/btpr.2721] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 08/30/2018] [Accepted: 09/20/2018] [Indexed: 12/15/2022]
Abstract
Biopharmaceutical protein manufacturing requires the highest producing cell lines to satisfy current multiple grams per liter requirements. Screening more clones increases the probability of identifying the high producers within the pool of available transfectant candidate cell lines. For the predominant industry mammalian host cell line, Chinese hamster ovary (CHO), traditional static‐batch culture screening does not correlate with the suspension fed‐batch culture used in manufacturing, and thus has little predictive utility. Small scale fed‐batch screens in suspension culture correlate better with bioreactor processes but a limited number of clones can be screened manually. Scaled‐down systems, such as shaken deep well plates, combined with automated liquid handling, offer a way for a limited number of scientists to screen many clones. A statistical analysis determined that 384 is the optimal number of clones to screen, with a 99% probability that six clones in the 95th percentile for productivity are included in the screen. To screen 384 clones efficiently by the predictive method of suspension fed‐batch, the authors developed a shaken deep‐well plate culturing platform, with an automated liquid handling system integrating cell counting and protein titering instruments. Critical factors allowing deep‐well suspension culture to correlate with shake flask culture were agitation speed and culture volume. Using our automated system, one scientist can screen five times more clones than by manual fed‐batch shake‐flask or shaken culture tube screens and can identify cell lines for some therapeutic protein projects with production levels greater than 6 g/L. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1460–1471, 2018
Collapse
Affiliation(s)
- Benjamin Wang
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Thomas Albanetti
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | | | - Layla Flack
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Lina Li
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Judith Klover
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Kerri Burson
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Krista Evans
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - William Ivory
- Analytical Biochemistry, MedImmune, Gaithersburg, Maryland, 20878
| | - Michael Bowen
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Ronald Schoner
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| | - Pamela Hawley-Nelson
- Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, 20878
| |
Collapse
|
12
|
Le K, Tan C, Gupta S, Guhan T, Barkhordarian H, Lull J, Stevens J, Munro T. A novel mammalian cell line development platform utilizing nanofluidics and optoelectro positioning technology. Biotechnol Prog 2018; 34:1438-1446. [PMID: 30009534 PMCID: PMC6585769 DOI: 10.1002/btpr.2690] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 06/26/2018] [Accepted: 06/27/2018] [Indexed: 12/21/2022]
Abstract
Generating a highly productive cell line is resource intensive and typically involves long timelines because of the need to screen large numbers of candidates in protein production studies. This has led to miniaturization and automation strategies to allow for reductions in resources and higher throughput. Current approaches rely on the use of standard cell culture vessels and bulky liquid handling equipment. New nanofludic technologies offer novel solutions to surpass these limits, further miniaturizing cell culture volumes (105 times smaller) by growing cells on custom nanofluidic chips. Berkeley Lights' OptoElectro Positioning technology projects light patterns to activate photoconductors that gently repel cells to manipulate single cells on nanofluidic culturing chips. Using a fully integrated technology platform (Beacon), common cell culture tasks can be programmed through software, allowing maintenance and analysis of thousands of cell lines in parallel on a single chip. Here, we describe the ability to perform key cell line development work on the Beacon platform. We demonstrate that commercial production Chinese hamster ovary cell lines can be isolated, cultured, screened, and exported at high efficiency. We compare this process head to head with a FACS-enabled microtiter plate-based workflow and demonstrate generation of comparable clonal cell lines with reduced resources. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1438-1446, 2018.
Collapse
Affiliation(s)
- Kim Le
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Christopher Tan
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Shivani Gupta
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Trupti Guhan
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Hedieh Barkhordarian
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Jonathan Lull
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Jennitte Stevens
- Drug Substance Technologies, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| | - Trent Munro
- Attribute Sciences, Process Development, Amgen Inc., Thousand Oaks, CA, 91320
| |
Collapse
|